126 related articles for article (PubMed ID: 31260716)
1. CD97 expression is associated with poor overall survival in acute myeloid leukemia.
Vaikari VP; Yang J; Wu S; Alachkar H
Exp Hematol; 2019 Jul; 75():64-73.e4. PubMed ID: 31260716
[TBL] [Abstract][Full Text] [Related]
2. CD97 is a critical regulator of acute myeloid leukemia stem cell function.
Martin GH; Roy N; Chakraborty S; Desrichard A; Chung SS; Woolthuis CM; Hu W; Berezniuk I; Garrett-Bakelman FE; Hamann J; Devlin SM; Chan TA; Park CY
J Exp Med; 2019 Oct; 216(10):2362-2377. PubMed ID: 31371381
[TBL] [Abstract][Full Text] [Related]
3. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.
Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U
Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
Garzon R; Volinia S; Papaioannou D; Nicolet D; Kohlschmidt J; Yan PS; Mrózek K; Bucci D; Carroll AJ; Baer MR; Wetzler M; Carter TH; Powell BL; Kolitz JE; Moore JO; Eisfeld AK; Blachly JS; Blum W; Caligiuri MA; Stone RM; Marcucci G; Croce CM; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18679-84. PubMed ID: 25512507
[TBL] [Abstract][Full Text] [Related]
5. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
Tiribelli M; Raspadori D; Geromin A; Cavallin M; Sirianni S; Simeone E; Bocchia M; Fanin R; Damiani D
Leuk Res; 2017 Jul; 58():31-38. PubMed ID: 28407515
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
7. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets.
Maiga A; Lemieux S; Pabst C; Lavallée VP; Bouvier M; Sauvageau G; Hébert J
Blood Cancer J; 2016 Jun; 6(6):e431. PubMed ID: 27258612
[TBL] [Abstract][Full Text] [Related]
9. Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.
Greiner J; Brown E; Bullinger L; Hills RK; Morris V; Döhner H; Mills KI; Guinn BA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638823
[TBL] [Abstract][Full Text] [Related]
10. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia.
Wu S; Du Y; Beckford J; Alachkar H
J Transl Med; 2018 Jun; 16(1):170. PubMed ID: 29925392
[TBL] [Abstract][Full Text] [Related]
12. Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia.
Hou HA; Lu JW; Lin TY; Tsai CH; Chou WC; Lin CC; Kuo YY; Liu CY; Tseng MH; Chiang YC; Peng YL; Tang JL; Gong Z; Lin LI; Tien HF
Blood Cancer J; 2017 Jul; 7(7):e588. PubMed ID: 28753595
[TBL] [Abstract][Full Text] [Related]
13. Loss of ZNF215 imprinting is associated with poor five-year survival in patients with cytogenetically abnormal-acute myeloid leukemia.
Yang MY; Lin PM; Yang CH; Hu ML; Chen IY; Lin SF; Hsu CM
Blood Cells Mol Dis; 2021 Sep; 90():102577. PubMed ID: 34091126
[TBL] [Abstract][Full Text] [Related]
14. Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.
Hömme C; Krug U; Tidow N; Schulte B; Kühler G; Serve H; Bürger H; Berdel WE; Dugas M; Heinecke A; Büchner T; Koschmieder S; Müller-Tidow C
Oncol Rep; 2010 Jul; 24(1):47-56. PubMed ID: 20514443
[TBL] [Abstract][Full Text] [Related]
15. NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome.
Handschuh L; Wojciechowski P; Kazmierczak M; Marcinkowska-Swojak M; Luczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
J Transl Med; 2018 Aug; 16(1):232. PubMed ID: 30126426
[TBL] [Abstract][Full Text] [Related]
16. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P; Marbello L; Borlenghi E; Fumagalli M; Bernardi M; Fracchiolla N; Mancini V; Da Vià M; Ravano E; Cerqui E; Ferretti VV; Rocca B; Calvello C; Cazzola M; Castagnola C; Rossi G
Ann Hematol; 2018 Nov; 97(11):2107-2115. PubMed ID: 30009341
[TBL] [Abstract][Full Text] [Related]
17. ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.
Tiribelli M; Geromin A; Cavallin M; Di Giusto S; Simeone E; Fanin R; Damiani D
Eur J Haematol; 2017 Sep; 99(3):269-274. PubMed ID: 28618016
[TBL] [Abstract][Full Text] [Related]
18. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ
Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
